** Test Mode **

  0.00 (USD)

This Package provides access to the entire event

Registration Header
REGISTER TODAY!

Goldfinch Bio KOL Event to Discuss the Unmet Need in FSGS and the Potential for GFB-887

Start Date:3/29/2022

Start Time:4:00 PM EDT

Duration:90 minutes

Abstract:

Goldfinch Bio’s virtual KOL event will discuss the unmet need in focal segmental glomerular sclerosis (FSGS), and the opportunity for the company’s lead product candidate, GFB-887, to deliver patients a disease-modifying precision medicine that can reduce proteinuria and potentially stop disease progression to provide patients years of preserved native kidney function, delaying kidney failure and the need for dialysis or transplant. Guest speaker Katherine Tuttle, M.D., FASN, FACP, FNKF, Executive Director for Research at Providence Health Care and Professor of Medicine at the University of Washington, will provide her perspective on the current treatment and clinical development landscape in FSGS and Goldfinch Bio management will review recently announced preliminary data from the ongoing Phase 2 clinical trial evaluating GFB-887 in FSGS.

If you're already registered for the Goldfinch Bio KOL Event to Discuss the Unmet Need in FSGS and the Potential for GFB-887 webcast, click below:

ALREADY REGISTERED?

Speakers

Anthony Johnson, M.D.

President and Chief Executive Officer

Goldfinch Bio, Inc.

Anthony Johnson, M.D. has served as President and Chief Executive Officer of Goldfinch Bio since December 2017. Prior to his role at Goldfinch, Dr. Johnson was Senior Vice President, Early Clinical Development and Chief Medical Officer of the Innovative Medicines and Early Development Biotech Unit at AstraZeneca from April 2014 to November 2017, and a Fellow at Homerton College, Cambridge, United Kingdom from March 2016 to November 2017. From October 2012 to December 2013, Dr. Johnson was a venture partner at OrbiMed Advisors. Dr. Johnson previously held positions as Vice President of Discovery Medicine and Clinical Pharmacology with Bristol-Myers Squibb from 2006 to 2012, as well as Vice President of Discovery Medicine at GlaxoSmithKline from 2001 to 2006 and served as the Founding Director of the GlaxoWelcome Medicines Research Unit from 1999 to 2001. He was a tenured Associate Professor of Medicine at the University of Queensland, Australia (1993 to 1999) prior to his industry experience. Dr. Johnson was a Board Director for Cardioxyl Pharmaceuticals from October 2012 to December 2015, and a Board Observer for Rgenix from January 2014 to August 2015. Dr. Johnson received an M.B.B.S. (1983) and M.D. (1993) from the University of New South Wales and his M.P.H. (1996) from the University of Queensland. He is a Fellow of the Royal Australasian College of Physicians and is board certified in internal medicine, geriatric medicine and clinical pharmacology.

Katherine Tuttle, M.D., FASN, FACP, FNKF

Executive Director for Research; Professor of Medicine

Providence Health Care; University of Washington

Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University School of Medicine in Chicago, Illinois. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis, Missouri. Her Nephrology fellowship training was performed at University of Texas Health Science Center in San Antonio, Texas. Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and chronic kidney disease. She has published over 250 original research contributions and served two terms as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients, Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington. Dr. Tuttle served on the Board of Directors for the Kidney Health Initiative and has chaired numerous kidney and diabetes related working groups and committees for organizations including the NIDDK/NIH, the National Kidney Foundation, the American Society of Nephrology, the International Society of Nephrology, and the American Diabetes Association.
Share on Facebook Share on Twitter Share on Linkedin Share through Email

Sponsors

Sponsor Image
Goldfinch Bio KOL Event to Discuss the Unmet Need in FSGS and the Potential for GFB-887
Registration Is Closed
© 2025 Brandlive. All rights reserved.
Already Registered? Technical Requirements System Check Port Troubleshooting